Author:
Barrachina Jordi,Margarit Cesar,Muriel Javier,López-Gil Santiago,López-Gil Vicente,Vara-González Amaya,Planelles Beatriz,Inda María-del-Mar,Morales Domingo,Peiró Ana M.
Abstract
AbstractTapentadol (TAP) and oxycodone/naloxone (OXN) potentially offer an improved opioid tolerability. However, real-world studies in chronic non-cancer pain (CNCP) remain scarce. Our aim was to compare effectiveness and security in daily pain practice, together with the influence of pharmacogenetic markers. An observational study was developed with ambulatory test cases under TAP (n = 194) or OXN (n = 175) prescription with controls (prescribed with other opioids (control), n = 216) CNCP patients. Pain intensity and relief, quality of life, morphine equivalent daily doses (MEDD), concomitant analgesic drugs, adverse events (AEs), hospital frequentation and genetic variants of OPRM1 (rs1799971, A118G) and COMT (rs4680, G472A) genes, were analysed. Test CNCP cases evidenced a significantly higher pain relief predictable due to pain intensity and quality of life (R2 = 0.3), in front of controls. Here, OXN achieved the greatest pain relief under a 28% higher MEDD, 8–13% higher use of pregabalin and duloxetine, and 23% more prescription change due to pain, compared to TAP. Whilst, TAP yielded a better tolerability due the lower number of 4 [0–6] AEs/patient, in front of OXN. Furthermore, OXN COMT-AA homozygotes evidenced higher rates of erythema and vomiting, especially in females. CNCP real-world patients achieved higher pain relief than other traditional opioids with a better tolerability for TAP. Further research is necessary to clarify the potential influence of COMT and sex on OXN side-effects.
Publisher
Springer Science and Business Media LLC
Reference56 articles.
1. Dowell, D., Haegerich, T. M. & Chou, R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recommend. Rep. 65, 1–49 (2016).
2. Hardt, J., Jacobsen, C., Goldberg, J., Nickel, R. & Buchwald, D. Prevalence of chronic pain in a representative sample in the United States. Pain Med. 9, 803–812 (2008).
3. Muriel, J. et al. Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients. Basic Clin. Pharmacol. Toxicol. https://doi.org/10.1111/bcpt.13155 (2019).
4. Fernandes, K. et al. High-Dose opioid prescribing and opioid-related hospitalization: A population-based study. PLoS ONE 11, e0167479 (2016).
5. Alexander, G., Frattaroli, S. & Gielen, A. The Prescription Opioid Epidemic: An Evidence-Based Approach (Johns Hopkins Bloomberg School of Public Health, 2015).
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献